Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,891 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,160 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05940116 | A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 322 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05802654 | Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer(USBRT-1) | not yet recruiting | N/A | 100 | Peking University Third HospitalOTHER | 1 | Jun 22, 2023 |
| NCT05904015 | The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05891080 | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial | not yet recruiting | Phase 2 | 124 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05881057 | Application of SERS Technology Based Intraoperative Navigation System in Lung Cancer | not yet recruiting | — | 200 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | May 30, 2023 | clinicaltrials |
| NCT05496166 | The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 348 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 17, 2023 | clinicaltrials |
| NCT05822284 | ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction Chemoimmunotherapy | not yet recruiting | — | 50 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03969693 | Lymphoma Patients Undergoing Mediastinal Radiotherapy in the Era of Modern Chemoradiation | not yet recruiting | — | 50 | Chang Gung Memorial HospitalOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05767892 | YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | not yet recruiting | Phase 3 | 350 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Apr 5, 2023 | clinicaltrials |
| NCT05784974 | Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung Cancer | not yet recruiting | Phase 2 | 37 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 27, 2023 | clinicaltrials |
| NCT05778149 | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation | not yet recruiting | Phase 2 | 47 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Mar 21, 2023 | clinicaltrials |
| NCT05698238 | Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours(CAMP1) | not yet recruiting | Phase 1 | 50 | Mabpro, a.s.INDUSTRY | 0 | Mar 15, 2023 | clinicaltrials |
| NCT05703997 | FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction(FASTIMMUNE) | not yet recruiting | Phase 2 | 20 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jan 30, 2023 | clinicaltrials |
| NCT05698264 | A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLC | not yet recruiting | N/A | 50 | Nir PeledOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05676788 | HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections(HYPER-Seg) | not yet recruiting | N/A | 50 | LungenClinic GrosshansdorfOTHER | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05621902 | Web-based Symptom Monitoring and Survival in Advanced Stage Lung Cancer(LUCA-S) | not yet recruiting | N/A | 398 | Mats LambeOTHER | 0 | Nov 18, 2022 | clinicaltrials |
| NCT05597800 | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome(LUNGVIR) | not yet recruiting | Phase 2 | 105 | Universita di VeronaOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05548504 | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC(HERAN2) | not yet recruiting | Phase 2 | 182 | Odense University HospitalOTHER | 0 | Sep 21, 2022 | clinicaltrials |
| NCT05484583 | Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases | not yet recruiting | Phase 2 | 58 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 0 | Aug 5, 2022 | clinicaltrials |
| NCT05186506 | A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 152 | Sichuan UniversityOTHER | 0 | Jan 11, 2022 | clinicaltrials |
| NCT05132985 | Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma | not yet recruiting | Phase 2 | 45 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT04846634 | Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)(ALTER-L043) | not yet recruiting | Phase 2 | 90 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT04772287 | Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008) | not yet recruiting | Phase 3 | 341 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Feb 26, 2021 | clinicaltrials |
| NCT03271749 | Protocol for Accelerated Recovery in Patients Undergoing Thoracic Surgical Procedures (PROSM). Study Randomized Comparative Between the Adoption of the Proposed Guidelines and the Traditional Method Currently Used in the Institution(PROSM) | not yet recruiting | N/A | 200 | Igor Renato Louro Bruno de AbreuOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04465968 | Efficacy and Safety of CRT, Durvalumab and Surgery for SST(DEEP_OCEAN) | not yet recruiting | Phase 3 | 84 | National Cancer Center Hospital EastOTHER | 0 | Jul 10, 2020 | clinicaltrials |
| NCT04153734 | Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC(Evolution) | not yet recruiting | Phase 2 | 21 | Kobe Minimally Invasive Cancer CenterOTHER | 0 | Nov 6, 2019 | clinicaltrials |
| NCT04049422 | Pulmonary Nodule Cohort(liquidNodule) | not yet recruiting | — | 1,000 | Seoul National University HospitalOTHER | 0 | Aug 8, 2019 | clinicaltrials |
| NCT03234179 | A Prognosis and Predicting Genetic Study of Lung Cancer | not yet recruiting | — | 500 | National Taiwan University HospitalOTHER | 0 | Aug 1, 2017 | clinicaltrials |
| NCT01595074 | Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy | not yet recruiting | — | 950 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jul 12, 2023source: clinicaltrials